4.2 Article

Vancomycin-Resistant Enterococci Therapeutic Challenges in the 21st Century

Journal

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
Volume 30, Issue 2, Pages 415-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.idc.2016.02.006

Keywords

Vancomycin resistant enterococcus; Antibiotic resistance; Combination therapy

Funding

  1. Theravance
  2. Bayer
  3. Cubist
  4. Forrest Pharmaceuticals
  5. Theravance Inc
  6. Johnson Johnson
  7. Astellas
  8. Palumed
  9. Intercell

Ask authors/readers for more resources

Vancomycin-resistant enterococci are serious health threats due in part to their ability to persist in rugged environments and their propensity to acquire antibiotic resistance determinants. Enterococci have now established a home in our hospitals and possess mechanisms to defeat most currently available antimicrobials. This article reviews the history of the struggle with this pathogen, what is known about the traits associated with its rise in the modern medical environment, and the current understanding of therapeutic approaches in severe infections caused by these microorganisms. As the 21st century progresses, vancomycin-resistant enterococci continue to pose a daunting clinical challenge.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available